Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations

Table 2 Associations between stimulant use and initiation on medication for opioid use disorder

Population	MOUD	aHR (95% CI)	p	Relative risk reduction (%)
CTN trials	Overall	0.68 (0.49, 0.94)	0.019	32
	Buprenorphine	0.67 (0.48, 0.92)	0.015	33
	XR-NTX	0.49 (0.28, 0.86)	0.013	51
NSDUH	Overall	0.75 (0.48, 1.18)	0.215	25
	Buprenorphine	0.77 (0.48, 1.23)	0.275	23
	XR-NTX	0.74 (0.31, 1.76)	0.496	26
TEDS	Overall	0.72 (0.51, 1.01)	0.061	28
	Buprenorphine	0.80 (0.55, 1.16)	0.241	20
	XR-NTX	0.68 (0.34, 1.36)	0.273	32
ROI	Overall	0.61 (0.35, 1.06)	0.081	39
	Buprenorphine	0.63 (0.33, 1.20)	0.161	37
	XR-NTX	0.24 (0.08, 0.69)	0.008	76

CTN National Drug Abuse Treatment Clinical Trials Network, NSDUH National Survey on Drug Use and Health, TEDS Treatment Episodes Dataset, ROI Rural Opioids Initiative, XR-NTX extended-release naltrexone, aHR adjusted hazard ratio

ISSN: 1940-0640